111 results about "Intra operative radiotherapy" patented technology

An apparatus and method for shielding non-target tissues and organs during thermotherapy, brachytherapy or other treatment of a diseased target tissue. The apparatus includes a catheter shaft having input and output lumens and at least one inflatable balloon. A plurality of input lumens within the catheter shaft allows the passage of liquid or gas through an input port and into the interior of the balloon thereby inflating the balloon. The gas or liquid can then be cycled through the inflated balloon through an output port and output lumen and out of the catheter shaft. Temperature sensors or other sensors may be attached to the balloon or catheter to monitor temperature or other conditions at the treatment site. The catheter is positioned between the target tissue or organ and sensitive non-target tissues in proximity to the target tissue and inflated causing a physical separation of tissues as well as a physical shield.

Electromedical apparatus for intraoperative radiotherapy via a linac. It includes an arm in which, at an extremity thereof, an oscillator is assembled which generates electromagnetic waves, and which supports, at an opposite extremity thereof, a radiating head in which a linac is assembled, emitting at its output an electron beam, supplied by the oscillator through a guiding structure. The apparatus includes a first and a second rotary couplings, respectively including a fixed portion and a mobile portion, endowed with sensors of the angular position of the mobile portions, which support the radiating head on the arm in roll and pitch motion. The guiding structure includes three separate rigid waveguides, of which one at the output of the oscillator and one of input to the linac, and an intermediate one therebetween, which connects them, with the heads of which they are respectively connected through the first and the second rotary couplings.

The invention relates generally to methods of using a thiol-Michael addition hydrogel for providing intracavitary brachytherapy and / or displacing tissue and organs. The thiol-Michael addition hydrogel may be used as a packing material and an attenuation material for intracavitary brachytherapy applications. The invention also relates generally to a brachytherapy applicator, which may be used in conjunction with the thiol-Michael addition hydrogel and methods thereof. The invention also relates to a kit comprising at least one container containing the precursor materials of the thiol-Michael addition hydrogel.

Provided is a method for analyzing the prognosis of cervical cancer according to the human papillomavirus (HPV) DNA integration pattern. The method of analyzing the prognosis of cervical cancer according to the human papillomavirus DNA integration pattern of the present invention enables an observation of the HPV DNA integration pattern with accuracy and convenience via in situ hybridization (ISH) compared to qPCR analysis. Since the prognosis of cervical cancer having the tumors with an episomal pattern and an integrated pattern can be significantly distinguished when the HPV DNA integration patterns are classified by the above method, the survival rate after radiotherapy of cervical cancer, and in particular invasive cervical cancer, can be more accurately analyzed.

The present invention is directed to a pharmaceutical composition comprising rebamipide having a mean particle size of less than 500 nm, a dispersing agent, and a viscosity enhancing agent wherein the viscosity enhancing agent has no aggregative action for the rebamipide particles, which is used as a gargle or a liquid preparation for swish and swallow comprising rebamipide for preventing and / or treating stomatitis caused by radiotherapy.

The invention provides a breast cancer patient radiotherapy tissue equivalent filler fixing device. The breast cancer patient radiotherapy tissue equivalent filler fixing device is composed of fillers, a pressing band, limiting holes, clips, unit parts, ventilating holes, trapezoid-shaped canvas, Velcro and a fixing pin, wherein the ventilating holes are formed in the trapezoid-shaped canvas, one end of the trapezoid-shaped canvas is connected with the Velcro, and the other end of the trapezoid-shaped canvas is provided with a row of unit parts with the limiting holes; the two ends of the pressing band are connected with the clips; the fillers 1 are located between two trapezoid-shaped canvas sheets and are fixed through the clips. The breast cancer patient radiotherapy tissue equivalent filler fixing device can better eliminate gaps between the body of a patient and the fillers and can further improve target region dosage except that close fitting is achieved. The breast cancer patient radiotherapy tissue equivalent filler fixing device can ensure more even whole-field radioactive ray dosage distribution and reduce irradiation field position deviations caused by involuntary movement of the patient after an irradiation body position is kept by the patient for a long time so as to smoothly finish irradiation. The breast cancer patient radiotherapy tissue equivalent filler fixing device is reasonable in design and easy to produce, achieves complex fitting of a physiological curved surface structure, is easy to operate when being used, and is suitable for tissue equivalent filler fixing in the breast cancer patient radiotherapy process.

A sustained release implant includes 0.1%-50% (w / w) nilotinib, 50-99% sustained release excipients and 0-15% sustained release moderator. Sustained release excipients are one or the combination of poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co- phosphoric acid propyl), glycolic acid and copolymer of glycolic acid and hydroxyacetic acid, and polifeprosan; sustained release moderator is one or combination of mannitol, sorbic alcohol and chondroitin; sustained release implant applied in local tumor can slowly release nilotinib onto local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction, thus the invention not only reduces overall toxic reaction of nilotinib, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy. The implant can be used for treating solid tumors including lung cancer, esophageal carcinoma, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic carcinoma, pancreatic cancer, bladder carcinoma, cerebroma, and colorectal cancer.

The invention relates to a mitoxantrone sustained-release implant capability of curing solid tumors, such as lung cancer, esophageal cancer, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic cancer, bladder cancer, colon cancer and rectum cancer. The invention is characterized in that: the sustained-release implant comprises mitoxantrone, sustained-release excipient and a certain amount of sustained-release regulator; the amount of the mitoxantrone and sustained-release excipient is sufficient to control cancer; the sustained-release excipient is mainly one or the combination of the copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly (L-lactide-co-ethyl phosphate) and poly (L-lactide-co-propyl phosphate); the mitoxantrone can be released slowly into part of the tumor during the degradation and adsorption, significantly reducing the systemic toxicity and sustaining the effective medicine concentration simultaneously. The invention has the advantages that: the systemic toxicity of mitoxantrone can be significantly reduced; the effective medicine concentration can be improved selectively at part of the tumor, and the therapeutic effects of non-operative treatments such as chemotherapeutic drugs and radiotherapy can be reinforced.

The invention relates to an imaging apparatus (24) for imaging an introduction element (17) like a needle or a catheter for performing a brachytherapy or a biopsy. A tracking unit (3, 4) tracks the location of the introduction element within a living being (2), an imaging unit (6) like an ultrasound imaging unit generates an image showing an inner part of the living being, which includes the tracked location of the introduction element, based on the tracked location, and a display (7) displays the image. During the brachytherapy or biopsy the display can always show the introduction element, without requiring a manual control. For instance, it is not necessary that a physician manually controls the position and image plane of the imaging unit. This allows for an accurate and fast insertion of the introduction element into the living being such that a target region is reliably reached.

A temozolomide sustained release implant for treating solid tumors is characterized in that the sustained release implant includes effective dose of anticancer temozolomide, sustained release excipients and a certain quantity of sustained release moderator. Solid tumors include pancreatic cancer, lung cancer, liver cancer, breast cancer, cerebroma, ovarian cancer, prostatic carcinoma, esophageal carcinoma, lymphadenoma, osteosarcoma and colorectal cancer. Sustained release excipients mainly are one or combination of copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, and poly(L-lactide-co-ethyl phosphate); in the process of decompression, temozolomide can be slowly released to local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction. Being placed in local tumor, the sustained release implant not only reduces overall toxic reaction of temozolomide, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy.

The invention relates to a fibrin glue composite system loaded with cisplatin. and specifically provides a fibrin glue, which is prepared from thrombin solution and fibrinogen solution as raw materials. The invention also provides a cisplatin / fibrin glue composite system which is prepared by taking a cisplatin solution, a thrombin solution and a fibrinogen solution as raw materials. The cisplatin / fibrin glue composite system has an excellent inhibition effect on postoperative growth of breast cancer, and has a good application prospect in preparation of drugs for treating tumors. More importantly, the cisplatin / fibrin glue composite system is combined with radiotherapy to play a synergistic interaction role in inhibiting recurrence of locally advanced breast cancer, and can more effectively inhibit recurrence of locally advanced breast cancer. Therefore, combined use of the fibrin glue composite system loaded with cisplatin with a radiotherapy device has broad application prospects inpreparing combined treatment equipment for treating tumors (especially locally advanced tumors).

The invention discloses an image-assisted cervical cancer patient prediction method, system and equipment, and the method comprises the steps: obtaining a CT image of a target cervical cancer patient, setting a region of interest of the CT image, extracting the radiomics characteristics of the region of interest of the CT image, and calculating the radiomics characteristics of the region of interest of the CT image; the optimal feature combination is calculated according to the radiomics features and the basic parameters of the target cervical cancer patient, the prognosis of the target cervical cancer patient after treatment is calculated according to the optimal feature combination, and the treatment prognosis is achieved through radiomics of the CT image of the radiotherapy planning system.